CD8A and neoplasm: To summarize, C-ter-J28+ DC-vaccinations led to an immune status characterized by expansion of anti-C-ter-J28+-tumor CD8+ T-cells, which in vitro specifically recognize Panc02 and kill them, and to NK cell activation.